SH3BP5 and diffuse large B-cell lymphoma: In the whole DLBCL cohort of 187 patients, SH3BP5 was positive in 60% (103 of 173), with LMO3 positive in 34% (59 of 175) and SNAP25 positive in 46% (77 of 168).